Major Symposium News Today

02.05.2024 - KT-474/SAR444656 (IRAK4) Phase 2 clinical trials ongoing in HS and AD with data expected in the first half of 2025 KT-621 (STAT6) expected to start Phase 1 in the second half of 2024 and KT-294 (TYK2) expected to start Phase 1 in the first half of ...

Targeted therapy, genomics, and treatment disparities were among the topics that were presented by researchers from UCSF at the 2024 AACR conference.

Presented new case studies demonstrating clinical responses in two patients with B cell malignancies, chronic lymphocytic leukemia (CLL) and primary...

Nurix Therapeutics, Inc. announced the presentation of the first findings of clinical responses in the brain for NX-5948, an orally available, selective degrader of Brutons tyrosine kinase . The...

New preclinical data on novel E3 pairing and structural mechanisms for KT-333, a First-in-Class STAT3 degrader, presented in AACR’s late-breaking poster session Nello Mainolfi, Founder, President and CEO of Kymera, invited as a featured speaker in AACR’s Major Symposium to discuss drug discovery and clinical translation strategies for STAT3 and MDM2 degrader programs KT-333 and KT-253 Phase 1 dose escalation studies ongoing with additional data expected in 2024 WATERTOWN, Mass., Ap...

For the first time in 15 years, the Marines can sport full-sleeve tattoos that cover most of their arms and legs according to the latest update on the Marine Corps tattoo policy on Friday.

Message : Required fields -- AFM24 preclinical in vivo data will be presented as a poster -- Data on AFM13 in combination with adoptive NK cells will be presented during a Major Symposium Heidelberg, Germany, March 10, 2021 -- Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, announced today that preclinical anti-tumor efficacy in vivo data from its innate cell engager (ICE(R) ) AFM...